Amid string of splashy pandemic IPOs, ADC returns for its millions
Six months after withdrawing their bid for a massive IPO, ADC Therapeutics is back with a more conservative number: $100 million.
The Swiss biotech had swung from huge funding round to huge funding round before, with its lead program nearing a regulatory submission. It filed for a $200 million IPO in September. They evidently found few takers, though, as they withdrew the bid within two weeks of pricing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
